Chinese vaccine gets go-ahead for trials in Bangladesh    | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
July 03, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, JULY 03, 2025
Chinese vaccine gets go-ahead for trials in Bangladesh   

Covid-19 in Bangladesh

TBS Report
23 June, 2021, 05:35 pm
Last modified: 23 June, 2021, 08:57 pm

Related News

  • Hundreds of millions of life years lost to pandemic: WHO
  • Ending the austerity pandemic
  • Asian shares head for worst month since pandemic started
  • Recovery in youth employment is still lagging: ILO
  • 5 reasons to be optimistic about 2022

Chinese vaccine gets go-ahead for trials in Bangladesh   

Another Chinese vaccine candidate awaits Bangladesh Medical Research Council approval

TBS Report
23 June, 2021, 05:35 pm
Last modified: 23 June, 2021, 08:57 pm
Scientists around the world are racing to develop a vaccine. Photo: Xinhua
Scientists around the world are racing to develop a vaccine. Photo: Xinhua

Bangladesh has approved phase III trials of a Chinese Covid-19 vaccine candidate developed by the Institute of Medical Biology of the Chinese Academy of Medical Sciences (IMBCAMS).

The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) will conduct the trial, Bangladesh Medical Research Council (BMRC) Chairman, Prof Dr Syed Modasser Ali, told The Business Standard Wednesday.

Approving the trials, the BMRC in a letter told icddr,b, "You have been approved to conduct the trial in accordance with the policy decision of the National Research Ethics Committee. Henceforth, the committee will be informed in more details."

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

The BMRC asked the icddr,b to inform them as to when and where the trails will take place so that the ethics committee can monitor it.

In August 2020, the Chinese vaccine developer contacted the icddr,b, and signed a clinical trial agreement.

In December last year, the icddr,b filed an application with the medical research council on behalf of the vaccine candidate and submitted a trial protocol.    

The vaccine candidate – SARS-CoV-2 Vaccine, Inactivated (Vero Cell) – is one of seven vaccines approved for use in China.

According to www.covid-19vaccinetracker.org, the phase I trial of this vaccine began in May 2020, and its results were released in October 2020. The phase II trial for it began in June 2020, while the IMBCAMS started phase III trials late January this year in Malaysia.

This vaccine trial candidate is an inactivated (vero cell) type of vaccine like polio and influenza. Such vaccines consist of viruses grown in culture and then killed as a means to reduce virulence, that is, the ability to infect and cause harm.

The dead virus prepares the body to initiate a defence mechanism if and when an individual contracts the germ in future.

One of the benefits of vero cell type vaccines is that they can be administered to people with weakened immune systems.

There is yet another Chinese vaccine candidate awaiting BMRC approval. 
 

Bangladesh / Top News

Covid-19 pandemic / Chinese vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • A meeting of the Advisory Council Committee chaired by the Chief Adviser Muhammad Yunus held on 3 July 2025. Photo: PID
    Govt Service (Amendment) Ordinance: Compulsory retirement to replace dismissal for misconduct in govt job 
  • A file photo of Colonel Md Shafiqul Islam of the Directorate of Military Operations briefing media. Photo: UNB
    Strict action if army personnel found involved in enforced disappearances: Army HQ
  • Former prime minister Sheikh Hasina. File photo: Collected
    Hasina's extradition request to be followed up: Foreign adviser

MOST VIEWED

  • Chief adviser’s Special Envoy for International Affairs and Adviser Lutfey Siddiqi
    Fake documents submission behind visa complications for Bangladeshis: Lutfey Siddiqi
  • Electric power transmission pylon miniatures and Adani Green Energy logo are seen in this illustration taken, on 9 December 2022. Photo: Reuters
    Bangladesh clears all dues to Adani Power
  • A file photo of the NBR Bhaban in Agargaon, Dhaka
    NBR officers gripped by fear as govt gets tough  
  • Controversial taxman Matiur’s rulings cost govt Tk1000cr in lost revenue
    Controversial taxman Matiur’s rulings cost govt Tk1000cr in lost revenue
  • History in women's football: Bangladesh qualify for Asian Cup for the first time
    History in women's football: Bangladesh qualify for Asian Cup for the first time
  • NBR Office in Dhaka. File Photo: Collected
    Govt sends 4 senior NBR officials on forced retirement

Related News

  • Hundreds of millions of life years lost to pandemic: WHO
  • Ending the austerity pandemic
  • Asian shares head for worst month since pandemic started
  • Recovery in youth employment is still lagging: ILO
  • 5 reasons to be optimistic about 2022

Features

Illustration: TBS

The buildup to July Uprising: From a simple anti-quota movement to a wildfire against autocracy

22h | Panorama
Illustration: TBS

Ulan Daspara: Remnants of a fishing village in Dhaka

2d | Panorama
Photo: Collected

Innovative storage accessories you’ll love

4d | Brands
Two competitors in this segment — one a flashy newcomer, the other a hybrid veteran — are going head-to-head: the GAC GS3 Emzoom and the Toyota CH-R. PHOTOS: Nafirul Haq (GAC Emzoom) and Akif Hamid (Toyota CH-R)

GAC Emzoom vs Toyota CH-R: The battle of tech vs trust

4d | Wheels

More Videos from TBS

News of The Day, 03 JULY 2025

News of The Day, 03 JULY 2025

42m | TBS News of the day
3 members of the same family beaten to death in Cumilla

3 members of the same family beaten to death in Cumilla

1h | TBS Today
Why is the US dollar falling to a record low in 2025?

Why is the US dollar falling to a record low in 2025?

2h | Others
Trump calls on US central bank head to quit immediately

Trump calls on US central bank head to quit immediately

3h | TBS World
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net